See a gap here that mirrors your own program? Start with a fixed-fee Readiness Assessment, or browse the IHASG safety-governance model.
Latest articles
Short summaries and downloadable white papers below. Click any card to read the full article.
The assumption baked into every pharmacovigilance system — and why it fails CAR-T patients
Conventional pharmacovigilance was built for drugs that reveal their toxicity slowly. CAR-T does the opposite — and the mismatch is a patient-safety problem, not a paperwork problem.
CAR-T toxicity 101: what every sponsor safety team needs before the first patient is dosed
A working orientation to CRS and ICANS for safety and clinical development teams — what to define before enrollment, not after the first event.
ADCs are not chemotherapy: a clinical briefing on organ-specific toxicity
Antibody-drug conjugates carry a targeted-toxicity profile that conventional chemotherapy monitoring is poorly shaped to catch. Treating them alike is a clinical safety error.
RLT safety monitoring: marrow reserve, renal function, and the dosimetry gap
Radioligand therapy carries a safety problem most pharmacovigilance teams are not trained to see — one that lives in cumulative dose, marrow reserve, and renal clearance.
The Acute Multi-Organ Instability Phase (AMOIP): a clinical reference
There is a clinical window in advanced-therapy toxicity that conventional pharmacovigilance was not designed to see. We call it AMOIP — and naming it changes how you govern it.
In the news
Press releases and media coverage about AyurDatta.
AyurDatta introduces IHASG and the Medical Oversight Workbench
AyurDatta formalizes Integrated High-Acuity Safety Governance (IHASG) and unveils the Medical Oversight Workbench — physician-in-the-loop safety oversight for the RTCT era.
AyurDatta attending 2025 Philly Momentum: In Vivo CAR-T & IIT Pathways
AyurDatta will attend Philly Momentum to engage with leaders in In Vivo CAR-T and IIT pathways.
Industry Veterans Dr. Ashok Srivastava and Elias Tharakan Launch AyurDatta
AyurDatta launches to bridge clinical science and AI-powered execution for biopharma innovators.